Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Q Fever is a global zoonotic disease caused by the bacterium Coxiella burnetii. Looking at market trends around Q Fever, it is clear that different factors are shaping diagnostics, treatment and prevention landscapes. In recent times, there has been a pronounced rise in awareness about zoonoses, which puts the Q Fever market on spotlight.
The development of diagnostics has thus propelled the trend in Q Fever markets. Doctors have to resort to more advanced diagnostic techniques as they grapple with an increased understanding of the disease’s intricacy. Serological tests, polymerase chain reaction (PCR) assays and culture methods play important roles in timely and accurate diagnosis. There is high demand for these diagnostics because quick identification of Q fever enables intervention and management.
Similarly, treatment protocols for Q Fever have shifted significantly illustrating changing market trends. Antibiotics especially doxycycline as well as fluoroquinolones are still used primarily during acute cases. However this is not the case when it comes to chronic forms of the illness where long courses of antibiotics are necessary often accompanied by surgery in some patients. In response to these challenges however, new drugs have been formulated and even combination therapies pursued by the industry players. This shows a dynamic situation regarding R&D efforts aimed at addressing complexities associated with management of Q Fever.
As far as preventing or curbing Q Fever is concerned vaccine development has become a key component within its market standing alongside public health strategies too because they are very necessary herein too when one looks at them from this perspective Vaccine development to reduce morbidity and mortality due to Q fever is considered significant hence effective ones must be developed and widely adopted across all economies Accordingly ongoing research has brought about positive developments that would assist in combating this zoonotic disease through vaccination technology campaigns aiming at sensitizing people about how q fever spreads plus prevention options so far done globally have considerably influenced marketplace dynamics.
Geographically, market trends in Q Fever vary due to factors such as climate, agricultural practices and veterinary policies. In regions where livestock are more prevalent, which also have increased interrelationship between animals and humans; there is a higher incidence of Q Fever. As such, these markets are characterized by an increased focus on diagnostics, treatment and preventive measures. Conversely, areas with a low prevalence may concentrate on preparedness for outbreaks or conducting awareness campaigns.
Technology is also driving market trends for Q Fever as it intersects with the healthcare sector. Telemedicine and digital health platforms allow remote consultations to be done hence timely diagnosis and treatment recommendations can be made. Additionally, digital platforms are being used as tools through which information about Q fever is being disseminated globally raising awareness among medical practitioners.
Q Fever Market Highlights:
Global Q Fever Market Overview
Q Fever Market Size was valued at USD 0.52 Billion in 2023. The Global Q Fever industry is projected to grow from USD 0.76 Billion in 2024 to USD 4.73 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.03% during the forecast period (2024 - 2032).
Some of the protuberant drivers supporting the growth of the Q fever market are identified as growth in the prevalence of chronic diseases and the increasing number of patients suffering from various bacterial infections.
The rising prevalence of Q fever coupled with increasing Q fever hospitalization rates, rising worldwide cattle, sheep, and goat population, growth in the risk factors of Q fever, and globally growing geriatric population are expected to drive the Q fever market in coming years.
Q Fever Market Trends
Q fever is a bacterial infection caused by the bacteria Coxiella (C.) burnetii. C. burnetii has a reservoir in birds and mammals, especially cattle, sheep, and goats, and is most often an occupational disease affecting farmers, veterinarians, and slaughterhouse workers. The Q fever infection, mostly chronic Q fever is severe with complications including endocarditis, encephalitis, pneumonia, hepatitis, and splenomegaly requiring hospitalization. As per the data provided by the Centers for Disease Control and Prevention (CDC), between 2002 and 2014, the Q fever hospitalization rates were increased from 25.0% to 68.0%. In the US, the prevalence of Q fever was high in four states, namely, California, Texas, Colorado, and Illinois. Additionally, in 2014, the highest incidence rate of Q fever which was at least 1.0 case per million persons was found in Arizona, Arkansas, Colorado, Idaho, Montana, Nebraska, North Dakota, Oregon, South Dakota, Utah, and West Virginia. Moreover, according to the European Centre for Disease Prevention and Control (ECDC), in 2016, 1,102 cases of Q fever were reported in the European Union (EU)/European Economic Area (EEA), out of which 1,058 (96%) were confirmed.
Q Fever Market Segment Insights
Q Fever Type Insights
Global Q fever, by type, segmented into acute and chronic. Chronic is the leading segment, which is growing at the highest CAGR to reach USD 706.20 thousand during the forecast period. Chronic Q fever is a life threating problem and causes damage to the heart, lungs, liver, brain, and could cause diabetes as well. The major share of the chronic segment is attributed to its high prevalence.
Q Fever Diagnosis Insights
Based on diagnosis, Q fever market is segmented into serology tests and others. The serology tests account for major share with 8.32% CAGR during the forecast period. Under the serology test, Q fever is diagnosed through antibody blood tests, polymerase chain reaction (PCR) tests, immunoperoxidase staining, complement fixation, enzyme-linked immunosorbent assay (ELISA) tests, and other molecular tests.
Q Fever Treatment Insights
The Q fever market, by treatment, is segmented into antibiotic and surgery. The antibiotics segment accounts for the second largest share in the market with 7.32% CAGR during the forecast period. Surgery is an important component of treatment if patients have extensive valvular damage or indications of heart failure.
Q Fever End User Insights
On the basis of end user, the market is segmented into patients, hospitals and clinics, and others. The patient segment accounted for a considerable market share of 72.1%.
Q Fever Regional Insights
The Asia-Pacific accounted for the largest market share of 44.5% and is projected to grow at the highest CAGR of 8.57% during the forecast period. The increasing prevalence of chronic diseases such as diabetes, cancer, and bacterial infection in developing countries is the major driver for market growth. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively.
The Asia-Pacific is followed by Europe, which accounted for a major market share. The European market is expected to grow at a strong growth rate during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with growing pet adoption.
The Americas accounted for a significant share in the Q fever market. It is attributed to the increasing adoption of pets, increasing preventive treatments, and care facilities for companion animals, rising technically advanced devices, and growing awareness regarding animal-transmitted diseases.
Q Fever Market Top Key Players
The prominent players in the Q fever market are
- Merck KGaA (Germany)
- Teva Pharmaceutical (Israel)
- Pfizer Inc. (US)
- Basilea Pharmaceutica Ltd (Switzerland)
- Sanofi S.A. (France)
- Melinta Therapeutics, Inc. (US)
- Bayer AG (Germany)
- Johnson & Johnson Services, Inc. (US)
- Yashica Pharmaceuticals (India)
- AtoxBio (US)
- Others
Some of the key strategies followed by the players operating in the Q fever market were innovation, product development, acquisition, and expansion.
- In September 2017, Basilea Pharmaceutica Ltd entered into a development, manufacturing, and commercialization agreement with Gosun Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Basilea's antibiotic ceftobiprole in China, Hong Kong, and Macao.
- In June 2017, Sanofi signed a strategic partnership with Eurapharma in Morocco. With this, Sanofi aims to strengthen its pharmaceutical business in Morocco and another African market.
- In June 2017, Melinta Therapeutics, Inc. got FDA approval for its antibiotic drug Baxdela (delafloxacin) for clinical indications such as infections.
Q Fever Market Segmentation
Q fever Type Outlook
- Acute
- Chronic
Q fever Diagnosis Outlook
- Serology Tests
- Others
Q fever Treatment Outlook
- Antibiotics
- Surgery
Q fever End User Outlook
- Patients
- Hospitals
- Others
Q fever Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- Russia
- France
- Italy
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
Available Additional Customizations
- Company Profiles of Other Key Players
- Cipla Inc. (India)
- CSL Limited (Australia)
Intended Audience
- Pharmaceutical Manufacturers and Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
